Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Protocols / Clinical Utility of Urinary CD90 as a Biomarker for Prostate Cancer Detection

Clinical Utility of Urinary CD90 as a Biomarker for Prostate Cancer Detection

201
Liu, Alvin Y.University of Washington
Liu, Alvin Y.University of Washington
CD90
Proteomics
Genomics
Prostate and Urologic Cancers Research Group
2

Tumor-associated stromal cells differ from normal gland-associated stromal cells in gene expression. Genes up-regulated in these stromal cells are potential cancer biomarkers, especially those encoding secreted or extracellular proteins. These proteins might be detected in urine. CD90/THY1 is one such candidate. A clinical test based on urinary CD90 would be useful in reducing the number of unnecessary biopsies done because of abnormal serum PSA and/or DRE finding. Elevated CD90 protein is found in tumor tissue and urine.

To develop multiple reaction monitoring (MRM) proteomics to measure CD90 in urine samples of pre-op(erative) prostate cancer, biopsy negative, post-op, pre-op bladder cancer, and non-cancer. MRM uses triple quadrupole mass spectrometer and synthetic isotopically labeled CD90 signature peptides for detection at the fmol level.
Genomic (Affymetrix GeneChip) analysis of sorted cancer cells and their normal counterpart (CD26+ prostate cancer vs. CD26+ luminal; CD90+ tumor-associated stromal vs. CD49a+ stromal; CD9+ bladder cancer vs. CD9+ superficial urothelial) to identify up-regulated genes encoding secreted or extracellular proteins. Proteomic analysis based on mass spectrometry to measure urinary levels of the protein candidates identified.
Since CD90 is expressed by many other cell types (e.g., T cells), its prostate cancer specificity as a urinary marker needs to be rigorously tested.

Announcement 06/30/2017

The next EDRN Steering Committee Meeting is from September 12-14, 2017, in Seattle WA. Please click here to register and find out more information about the meeting.

Announcement



EDRN Founder Honored

Dr. Sudhir Srivastava was honored with the Distinguished Service Award from the American Pancreatic Association at the group's annual meeting this year, for his outstanding commitment to pancreatology.